Kobby Asubonteng

Novartis Pharmaceuticals Corporation
Clinical Development
Papers:
FP27-3 Inhibition of GH and IGF-1 Is Maintained with Pasireotide LAR and Octreotide LAR in Patients with Acromegaly: 12-Month Extension Phase of a Double-Blind, Multicenter, Randomized, Phase III Study